Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LDN-214117
Cat. No.:
OB0225LY-0184
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
LDN-214117 is an emerging molecule that plays a key role in signaling pathways.
Synonym:
1627503-67-6; 1-(4-(6-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl)phenyl)piperazine; LDN 214117; 1-[4-[6-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenyl]piperazine; 1-{4-[6-Methyl-5-(3,4,5-trimethoxyphenyl)pyridin-3-yl]phenyl}piperazine
CAS No.:
1627503-67-6
Compound CID:
91754554
Formula:
C25H29N3O3
Formula Weight:
419.52
Specification
Relative Density:
1.134 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
LDN-214117 can be used in signal transduction studies or play an important role in cell transformation studies.
Library Information
Targets:
TGF-beta/Smad; ALK family
Receptors:
ALK2; TGF-β receptor
Pathways:
Tyrosine kinase/adaptors; Stem cells; Angiogenesis
Plate Number:
AOCL-3
Plate Location:
c8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
4.2 mg/mL; 10 mM
Ethanol Max Solubility:
42 mg/mL; 100 mM
ALogP:
3.533
HBA_Count:
4
HBD_Count:
1
Rotatable Bond:
6
